- $1.33bn
- $953.14m
- $2.37m
- 35
- 10
- 53
- 23
Annual cashflow statement for Upstream Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -23.9 | -20.5 | -62.8 |
| Depreciation | |||
| Non-Cash Items | 1.43 | -13.3 | 1.67 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 3.41 | -4.17 | 1.87 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -19 | -37.9 | -59.2 |
| Capital Expenditures | -0.082 | -0.144 | -0.511 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | 0 | -82.7 | -59 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -0.082 | -82.8 | -59.5 |
| Financing Cash Flow Items | — | — | -3.9 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 9.96 | 130 | 419 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -9.14 | 8.78 | 300 |